Novo Nordisk Inc v. Orbicular Pharmaceutical Tech Pvt Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Novo Nordisk Inc. (Delaware) and Novo Nordisk A/S (Denmark)
  • Defendant: Orbicular Pharmaceutical Technologies Pvt. Ltd. (India)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
• Case Identification: 1:23-cv-00179, D. Del., 02/17/2023
• Venue Allegations: Plaintiff alleges venue is proper in the District of Delaware because Defendant has conducted business in the state, derived revenue from the state, engaged in systematic and continuous contacts, and previously consented to personal jurisdiction in the district in separate litigation.
• Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's Victoza® product constitutes an act of infringement of two patents related to pharmaceutical formulations and injection device technology.
• Technical Context: The dispute involves a pharmaceutical formulation for a GLP-1 agonist peptide used in diabetes treatment and the mechanical design of a push button for the corresponding injection pen.
• Key Procedural History: The action arises under the Hatch-Waxman Act, triggered by Defendant's submission of ANDA No. 217590 with a Paragraph IV Certification. The complaint notes that Defendant's certification alleges the asserted patents are invalid or will not be infringed. A prior case between the parties in the same district is cited to support personal jurisdiction.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,114,833 - "Propylene Glycol-Containing Peptide Formulations Which Are Optimal for Production and for Use in Injection Devices," issued February 14, 2012

The Invention Explained

• Problem Addressed: The patent describes a problem with using mannitol, a common agent for ensuring proper isotonicity (the concentration of solutes) in injectable peptide drugs. Mannitol can crystallize during production, leading to deposits on manufacturing equipment and, critically, clogging the fine needles of injection devices used by patients ʼ833 Patent, col. 1:30-45
• The Patented Solution: The invention replaces mannitol with propylene glycol as the isotonicity agent in peptide formulations. This change is asserted to reduce the formation of deposits during the manufacturing filling process and to reduce the clogging of injection device needles, thereby improving production efficiency and patient usability ʼ833 Patent, abstract ʼ833 Patent, col. 1:52-58
• Technical Importance: Developing stable, reliable, and easily manufacturable liquid formulations for injectable biologics is critical for patient-administered therapies, as issues like needle clogging can deter compliance and affect dose accuracy.

Key Claims at a Glance

• The complaint asserts claims 1-31 Compl. ¶20 Independent claim 1 is representative of the formulation claims.
• Independent Claim 1 Elements:
  • A pharmaceutical formulation comprising at least one GLP-1 agonist,
  • a disodium phosphate dihydrate buffer, and
  • propylene glycol,
  • wherein said propylene glycol is present in said formulation in a final concentration of from about 1 mg/ml to about 100 mg/ml, and
  • wherein said formulation has a pH of from about 7.0 to about 10.0.

U.S. Patent No. 9,265,893 - "Injection Button," issued February 23, 2016

The Invention Explained

• Problem Addressed: In pen-style injection devices, setting a dose often involves rotating a dial. When the user pushes the injection button, the internal driving mechanism must rotate back to its original position to expel the drug. This relative rotation between the stationary push button (held by the user's thumb) and the rotating internal driver creates friction, which increases the force a user must apply to administer the injection ʼ893 Patent, col. 1:26-34
• The Patented Solution: The invention is a specific mechanical connection between the push button and the driving part that is designed to minimize this rotational friction. The core of the solution is a "pivot bearing" formed between the button and a protrusion on the driving part, which concentrates the axial force over a small area. This design aims to make the injection process smoother and require less force from the user ʼ893 Patent, abstract ʼ893 Patent, col. 2:54-61
• Technical Importance: For patients who self-administer frequent injections, particularly those with reduced dexterity, minimizing the required actuation force is a significant factor in device usability and treatment adherence.

Key Claims at a Glance

• The complaint asserts claims 1-6 Compl. ¶26 Claim 1 is the sole independent claim.
• Independent Claim 1 Elements:
  • A push button connection for an injection device comprising: a push button mountable on a driving part,
  • the push button being rotatable relatively to the driving part,
  • the push button further comprises a bore with a bottom surface which surrounds a protrusion on the driving part,
  • the protrusion has a top surface,
  • a pivot bearing is formed between the bottom surface [of the bore] and the top surface [of the protrusion],
  • wherein when a user presses on the push button the force is directed toward the driving part, and
  • the driving part rotates relative to the push button.

III. The Accused Instrumentality

Product Identification

Defendant's proposed generic version of liraglutide injection solution, 18 mg/3 ml (6 mg/ml), as described in ANDA No. 217590 ("Orbicular's Product") Compl. ¶15

Functionality and Market Context

The accused product is a generic drug intended to be a bioequivalent version of Plaintiff's Victoza® product Compl. ¶1 Compl. ¶16 Victoza® is a GLP-1 receptor agonist used for the treatment of type 2 diabetes. The complaint alleges that Orbicular's ANDA refers to and relies upon the Victoza® New Drug Application (NDA) Compl. ¶16 The infringement allegations cover both the drug formulation itself and the injection device with which it is intended to be used Compl. ¶20 Compl. ¶26

IV. Analysis of Infringement Allegations

The complaint does not provide sufficient detail for a claim-chart analysis. The infringement counts are pleaded at a high level, asserting that the act of filing the ANDA for a product that will be manufactured and sold constitutes infringement under 35 U.S.C. § 271(e)(2)(A) Compl. ¶19 Compl. ¶25

• Infringement Theory for the '833 Patent: The complaint alleges that the manufacture, use, or sale of Orbicular's Product would infringe claims 1-31 of the '833 patent Compl. ¶20 The implicit theory is that for Orbicular's Product to be bioequivalent to Victoza®, its formulation must contain a GLP-1 agonist (liraglutide) and propylene glycol as an isotonicity agent, thereby meeting the limitations of at least claim 1. The complaint notes that Defendant's Paragraph IV letter did not contest infringement of the '833 patent but contended the claims are invalid Compl. ¶20
• Infringement Theory for the '893 Patent: The complaint alleges that the manufacture, use, or sale of Orbicular's Product would infringe claims 1-6 of the '893 patent Compl. ¶26 This allegation suggests that the drug product is intended for administration with an injection device, such as a disposable pen, that incorporates the patented push button connection. No specific device is identified or analyzed in the complaint.
• Identified Points of Contention:
  • Scope Questions: For the '833 patent, a central question will be whether the specific concentration of propylene glycol and the pH of Orbicular's formulation, as detailed in its confidential ANDA, fall within the ranges claimed (e.g., "from about 1 mg/ml to about 100 mg/ml"). The interpretation of the term "about" may be a point of dispute. For the '893 patent, the dispute may center on whether the term "pivot bearing," as defined and illustrated in the patent, reads on the specific mechanical interface in the delivery device intended for use with Orbicular's Product.
  • Technical Questions: A primary technical question for the '893 patent is whether the delivery device for the generic product actually practices the claimed combination of a pivot bearing and relative rotation between the button and driver. The complaint provides no evidence to substantiate this allegation. For the '833 patent, while infringement is reportedly not contested, the defendant's invalidity challenge will likely raise technical questions regarding whether the use of propylene glycol as a substitute for mannitol was obvious to a person of ordinary skill in the art of pharmaceutical formulation at the time of the invention.

No probative visual evidence provided in complaint.

V. Key Claim Terms for Construction

• For the '833 Patent:

  • The Term: "about 1 mg/ml to about 100 mg/ml" (from Claim 1)
  • Context and Importance: The scope of this concentration range is dispositive for literal infringement. Whether Orbicular's specific formulation falls within this range will depend on the latitude afforded by the word "about." Practitioners may focus on this term because even a small deviation from the recited numerical endpoints could be the basis for a non-infringement argument.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The use of the word "about" itself suggests the patentee did not intend to be limited to the exact numerical values. The specification provides numerous examples with specific concentrations (e.g., 13.7 mg/ml, 14.0 mg/ml, 14.3 mg/ml) that could be used to argue for a reasonable range around the claimed endpoints ʼ833 Patent, col. 16:8 ʼ833 Patent, col. 20:15
    • Evidence for a Narrower Interpretation: A defendant may argue that the range should be interpreted narrowly, limited to what the specification demonstrates as effective. The patent emphasizes that the formulations are "optimal for production and for use" ʼ833 Patent, title, which could be used to argue that the "about" term does not extend to concentrations that fail to provide these optimal results.

• For the '893 Patent:

  • The Term: "pivot bearing" (from Claim 1)
  • Context and Importance: This term is the central novel feature of the claimed injection button. The entire theory of reduced friction depends on the specific structure and function of this element. Infringement will hinge on whether the accused device contains a structure that meets the definition of a "pivot bearing" as described in the patent.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: A plaintiff may argue that "pivot bearing" should be construed functionally to cover any interface that concentrates axial force to a point or small area to reduce rotational friction. The patent's "Description of the Invention" section states the goal is to form a pivot bearing "to minimize this friction" ʼ893 Patent, col. 2:54-58, supporting a functional interpretation.
    • Evidence for a Narrower Interpretation: The specification provides a specific structural embodiment: "the pivot 18 formed in the most proximal bottom surface 17 of the bore 12 bears on the top surface 22 of the protrusion 21 thus forming a pivot bearing 22, 18" ʼ893 Patent, col. 4:15-18 A defendant may argue that the term should be limited to this specific point-on-surface contact geometry, as depicted in the figures, and does not cover other types of low-friction rotational interfaces.

VI. Other Allegations

• Indirect Infringement: The complaint does not plead induced or contributory infringement in the traditional sense. It relies on the statutory act of infringement created by 35 U.S.C. § 271(e)(2)(A), which defines the submission of an ANDA seeking approval to market a drug claimed in a patent as an act of infringement Compl. ¶19 Compl. ¶25
• Willful Infringement: The complaint alleges that Defendant "was aware of the '833 patent when it submitted its ANDA" and "was aware of the '893 patent when it submitted its ANDA" Compl. ¶23 Compl. ¶29 Based on this alleged pre-suit knowledge, Plaintiff requests a finding that the case is "exceptional" and an award of attorney's fees under 35 U.S.C. § 285 Compl. Prayer for Relief F

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue for the '833 patent will be one of validity: Given that Defendant's Paragraph IV notice allegedly concedes infringement, the case will likely center on whether the claimed formulation-substituting propylene glycol for other known isotonicity agents like mannitol-was an obvious modification to a person of ordinary skill in the art at the time of the invention.
• A key evidentiary question for the '893 patent will be one of technical infringement: Does the specific injection device intended for use with Defendant's generic product incorporate the "pivot bearing" structure as claimed? The resolution of this issue will depend on a factual comparison of the accused device's mechanics with the patent's claims and specification.
• A central procedural question will be the scope of discovery: Since the infringement allegations rest on the contents of a confidential ANDA filing, the case will proceed through discovery to reveal the exact composition of the accused formulation and the design of its intended delivery device, which will either substantiate or undermine the complaint's high-level allegations.